JP2008521831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521831A5 JP2008521831A5 JP2007543613A JP2007543613A JP2008521831A5 JP 2008521831 A5 JP2008521831 A5 JP 2008521831A5 JP 2007543613 A JP2007543613 A JP 2007543613A JP 2007543613 A JP2007543613 A JP 2007543613A JP 2008521831 A5 JP2008521831 A5 JP 2008521831A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- optionally
- substituted lower
- heterocycloalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003342 alkenyl group Chemical group 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 18
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 18
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 150000001336 alkenes Chemical class 0.000 claims 12
- 150000001345 alkine derivatives Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007749 Cataract diabetic Diseases 0.000 claims 1
- 108700012841 Cholesteryl Ester Transfer Protein Deficiency Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000007025 diabetic cataract Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000015076 hyperalphalipoproteinemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63189304P | 2004-11-30 | 2004-11-30 | |
| US71525805P | 2005-09-07 | 2005-09-07 | |
| PCT/US2005/043412 WO2006060535A2 (en) | 2004-11-30 | 2005-11-29 | Indole derivatives for use as ppar active compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521831A JP2008521831A (ja) | 2008-06-26 |
| JP2008521831A5 true JP2008521831A5 (enExample) | 2009-01-22 |
Family
ID=36284449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543613A Pending JP2008521831A (ja) | 2004-11-30 | 2005-11-29 | Ｐｐａｒ活性化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060135540A1 (enExample) |
| EP (1) | EP1833787A2 (enExample) |
| JP (1) | JP2008521831A (enExample) |
| AU (1) | AU2005311826A1 (enExample) |
| CA (1) | CA2589896A1 (enExample) |
| WO (1) | WO2006060535A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629473B2 (en) * | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
| AR054393A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| WO2007127791A2 (en) * | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
| CA2680625C (en) | 2007-03-14 | 2016-02-23 | Ranbaxy Laboratories Limited | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
| CA2695004C (en) | 2007-07-17 | 2016-01-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB0715048D0 (en) * | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel compounds |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP5508400B2 (ja) * | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| WO2009147190A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| JP5502076B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規化合物 |
| ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
| UY32585A (es) | 2009-04-30 | 2010-11-30 | Glaxo Group Ltd | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa |
| KR20120097512A (ko) | 2009-11-18 | 2012-09-04 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| EP2516438A4 (en) | 2009-12-23 | 2013-06-12 | Plexxikon Inc | COMPOUNDS AND METHODS FOR KINASE MODULATION AND DISPLAYS THEREFOR |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| TR201816421T4 (tr) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları. |
| EP3552664A1 (en) | 2011-05-12 | 2019-10-16 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| AU2013312477B2 (en) | 2012-09-06 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2912036A1 (en) | 2012-10-04 | 2015-09-02 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
| SG11201504754QA (en) | 2012-12-21 | 2015-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| PT2970265T (pt) | 2013-03-15 | 2018-10-23 | Plexxikon Inc | Compostos heterocíclicos e suas utilizações |
| WO2014194127A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP3194392B1 (en) | 2014-09-15 | 2020-01-01 | Plexxikon, Inc. | Heterocyclic compounds and uses thereof |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP4071149A3 (en) | 2015-09-21 | 2023-01-25 | Opna Immuno Oncology, SA | Heterocyclic compounds and uses thereof |
| BR112018011475A2 (pt) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compostos e métodos para modulação de quinase e indicação para a mesma |
| CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| EP3430005B1 (en) | 2016-03-16 | 2021-12-08 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| TW201819361A (zh) | 2016-09-03 | 2018-06-01 | 印度商托仁特生技有限公司 | 新穎吲唑化合物 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| TWI805599B (zh) | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | 激酶調節化合物之調配物 |
| AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
| CN109678784A (zh) * | 2017-10-19 | 2019-04-26 | 天津师范大学 | 硫醚化吲哚类化合物及其制备方法 |
| CA3080197C (en) | 2017-10-27 | 2023-12-19 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法，以及其适应症 |
| CA3137091A1 (en) | 2019-06-17 | 2020-12-24 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
| JP2023524465A (ja) | 2020-04-29 | 2023-06-12 | プレキシコン インコーポレイティド | 複素環式化合物の合成 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3511841A (en) * | 1967-05-29 | 1970-05-12 | Sterling Drug Inc | 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines |
| US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| US5075313A (en) * | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
| DK0753511T3 (da) * | 1994-03-30 | 2001-09-24 | Zeria Pharm Co Ltd | 4-indol-1-ylsmørsyrederivater, deres fremstilling og deres anvendelse som inhibitorer af alfa 1-adrenerge receptorer og testosteron-5alfa-reduktaser |
| EA005244B1 (ru) * | 1998-02-23 | 2004-12-30 | Саут Алабама Медикал Сайенс Фаундейшн | Индол-3-пропионовые кислоты, их соли и эфиры, используемые в качестве лекарств |
| CA2327695A1 (en) * | 1998-04-08 | 1999-10-21 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| US6608059B1 (en) * | 2000-06-27 | 2003-08-19 | Smithkline Beecham Corporation | Fatty acid synthase inhibitors |
| CA2460313C (en) * | 2001-09-14 | 2011-03-08 | Tularik Inc. | Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
| DE60308670T2 (de) * | 2002-02-01 | 2007-08-16 | F. Hoffmann-La Roche Ag | Substituierte indole als alpha-1 agonisten |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| NZ538031A (en) * | 2002-08-29 | 2007-10-26 | Merck & Co Inc | Indoles having anti-diabetic activity |
| JP4845730B2 (ja) * | 2003-07-17 | 2011-12-28 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| BRPI0415437A (pt) * | 2003-10-14 | 2006-12-05 | Oxagen Ltd | composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto |
| WO2005056522A2 (en) * | 2003-12-04 | 2005-06-23 | National Health Research Institutes | Indole compounds |
| GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
-
2005
- 2005-11-29 JP JP2007543613A patent/JP2008521831A/ja active Pending
- 2005-11-29 EP EP05852598A patent/EP1833787A2/en not_active Withdrawn
- 2005-11-29 CA CA002589896A patent/CA2589896A1/en not_active Abandoned
- 2005-11-29 WO PCT/US2005/043412 patent/WO2006060535A2/en not_active Ceased
- 2005-11-29 US US11/289,781 patent/US20060135540A1/en not_active Abandoned
- 2005-11-29 AU AU2005311826A patent/AU2005311826A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521831A5 (enExample) | ||
| JP2008521829A5 (enExample) | ||
| JP2009507079A5 (enExample) | ||
| JP2009509932A5 (enExample) | ||
| JP2009507846A5 (enExample) | ||
| JP2010526145A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| RU2009137124A (ru) | Соединения, активные в отношении ppar | |
| JP2010514829A5 (enExample) | ||
| JP2009541269A5 (enExample) | ||
| JP2013504613A5 (enExample) | ||
| JP6238460B2 (ja) | 脂質異常症治療剤 | |
| JP2009541270A5 (enExample) | ||
| JP2009531280A5 (enExample) | ||
| JP2013526494A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2011513476A5 (enExample) | ||
| HUE024898T2 (en) | New pyrimidine compound with dibenzylamine structure and drug containing compound | |
| RU2008110697A (ru) | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) | |
| JP2008520742A5 (enExample) | ||
| JP5291708B2 (ja) | アリールピリミジン誘導体、その製造方法、及び、その使用 | |
| JP2012520252A (ja) | Ｄｈｏｄｈ阻害剤としての、ヒドロキシル基および／またはカルボキシル基含有アミンとアミノニコチン酸誘導体との付加塩 | |
| JP2012255002A5 (enExample) | ||
| JP2015505301A5 (enExample) | ||
| JP2009528275A5 (enExample) |